Determination of the frequency of hyperprolactinemia-related etiologies and the etiology-specific mean prolactin levels.

IF 2.5 Q3 ENDOCRINOLOGY & METABOLISM Minerva endocrinology Pub Date : 2024-09-01 Epub Date: 2021-09-16 DOI:10.23736/S2724-6507.21.03386-8
Fatma N Korkmaz, Asena Gökçay Canpolat, Mustafa Şahin, Demet Çorapçioğlu
{"title":"Determination of the frequency of hyperprolactinemia-related etiologies and the etiology-specific mean prolactin levels.","authors":"Fatma N Korkmaz, Asena Gökçay Canpolat, Mustafa Şahin, Demet Çorapçioğlu","doi":"10.23736/S2724-6507.21.03386-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Prolactin (PRL) is a peptide hormone secreted by the anterior pituitary that provides lactation during the postpartum period. The causes of hyperprolactinemia are pituitary tumors, medications, primary hypothyroidism, polycystic ovary syndrome (PCOS), renal failure, idiopathic, and other physiological causes such as pregnancy and lactation. In this study, we aimed to investigate the prevalence of hyperprolactinemia etiologies and the mean/median prolactin levels in different etiologies.</p><p><strong>Methods: </strong>The patients admitted to our outpatient clinic between January 2009-December 2019 were retrospectively screened from our hospital database with ICD-10 codes. Four hundred patients were included in the study; 69.5% of the patients were women. Their mean age was 43.67±13.42 years, the duration of illness was 7.8±5.6 years. The most frequent causes of hyperprolactinemia were found as follows: 52.5% (N.=210) prolactinoma, 7% (N.=28) gonadotropinoma, 6.5% (N.=26) drug-related, 6.5% (N.=25) PCOS, 5.8% (N.=23) idiopathic, 5% (N.=20) acromegaly, 4.8% (N.=19) nonfunctioning adenoma 2.3% (N.=9) craniopharyngioma. Patients with gonodotropinoma were significantly older, and the patients with PCOS were significantly younger than the patients with hyperprolactinemia due to the other etiologies. Patients with prolactinoma had significantly higher prolactin levels and longer duration of the illness when compared to other etiologies of hyperprolactinemia (168.00* ng/mL [14-23,500] [168]); 8* years (0-39) (5.00) years respectively, *median values, (min-max levels) and (interquartile range), respectively.</p><p><strong>Results: </strong>There was no significant difference between prolactin levels of other etiologic groups except prolactinoma. Surprisingly, we found PCOS patients with prolactin levels greater than 100 ng/mL and acromegaly or drug-induced hyperprolactinemia with prolactin levels greater than 200 ng/mL. In our study, unlike the literature, macroprolactinemia can be seen alone or together with other pathologies. Except for macroprolactinoma, it is not possible to diagnose according to prolactin level. Similar to the literature, prolactinoma was the most common cause of hyperprolactinemia. The causes of hyperprolactinemia, in order of decreasing frequency, were determined to be gonodotropinoma, drug-related, PCOS, idiopathic, and acromegaly. The range of prolactin detected in PCOS is given as new information. It was found that the pediatric group and the adult group had a similar etiology and PRL level.</p><p><strong>Conclusions: </strong>A large spectrum of physiologic/pathologic conditions increases the prolactin levels, and prolactin levels may vary from person to person. So, the serum prolactin level alone does not guide a clinical diagnosis or make a differential diagnosis.</p>","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":"243-252"},"PeriodicalIF":2.5000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minerva endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23736/S2724-6507.21.03386-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/9/16 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Prolactin (PRL) is a peptide hormone secreted by the anterior pituitary that provides lactation during the postpartum period. The causes of hyperprolactinemia are pituitary tumors, medications, primary hypothyroidism, polycystic ovary syndrome (PCOS), renal failure, idiopathic, and other physiological causes such as pregnancy and lactation. In this study, we aimed to investigate the prevalence of hyperprolactinemia etiologies and the mean/median prolactin levels in different etiologies.

Methods: The patients admitted to our outpatient clinic between January 2009-December 2019 were retrospectively screened from our hospital database with ICD-10 codes. Four hundred patients were included in the study; 69.5% of the patients were women. Their mean age was 43.67±13.42 years, the duration of illness was 7.8±5.6 years. The most frequent causes of hyperprolactinemia were found as follows: 52.5% (N.=210) prolactinoma, 7% (N.=28) gonadotropinoma, 6.5% (N.=26) drug-related, 6.5% (N.=25) PCOS, 5.8% (N.=23) idiopathic, 5% (N.=20) acromegaly, 4.8% (N.=19) nonfunctioning adenoma 2.3% (N.=9) craniopharyngioma. Patients with gonodotropinoma were significantly older, and the patients with PCOS were significantly younger than the patients with hyperprolactinemia due to the other etiologies. Patients with prolactinoma had significantly higher prolactin levels and longer duration of the illness when compared to other etiologies of hyperprolactinemia (168.00* ng/mL [14-23,500] [168]); 8* years (0-39) (5.00) years respectively, *median values, (min-max levels) and (interquartile range), respectively.

Results: There was no significant difference between prolactin levels of other etiologic groups except prolactinoma. Surprisingly, we found PCOS patients with prolactin levels greater than 100 ng/mL and acromegaly or drug-induced hyperprolactinemia with prolactin levels greater than 200 ng/mL. In our study, unlike the literature, macroprolactinemia can be seen alone or together with other pathologies. Except for macroprolactinoma, it is not possible to diagnose according to prolactin level. Similar to the literature, prolactinoma was the most common cause of hyperprolactinemia. The causes of hyperprolactinemia, in order of decreasing frequency, were determined to be gonodotropinoma, drug-related, PCOS, idiopathic, and acromegaly. The range of prolactin detected in PCOS is given as new information. It was found that the pediatric group and the adult group had a similar etiology and PRL level.

Conclusions: A large spectrum of physiologic/pathologic conditions increases the prolactin levels, and prolactin levels may vary from person to person. So, the serum prolactin level alone does not guide a clinical diagnosis or make a differential diagnosis.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
确定高催乳素血症相关病因的频率和病因特异性平均催乳素水平。
背景:催乳素(PRL)是垂体前叶分泌的一种肽类激素,在产后提供泌乳功能。导致高催乳素血症的原因包括垂体肿瘤、药物、原发性甲状腺功能减退症、多囊卵巢综合征(PCOS)、肾功能衰竭、特发性以及妊娠和哺乳等其他生理原因。本研究旨在调查高催乳素血症病因的发生率以及不同病因的催乳素平均/中位水平:方法:从我院数据库中使用 ICD-10 编码对 2009 年 1 月至 2019 年 12 月期间门诊收治的患者进行回顾性筛选:研究共纳入400名患者。69.5%的患者为女性。平均年龄为(43.67±13.42)岁,病程为(7.8±5.6)年。高催乳素血症最常见的病因如下:52.5%(n:210)催乳素瘤,7%(n:28)促性腺激素瘤,6.5%(n:26)药物相关,6.5%(n:25)多囊卵巢综合征,5.8%(n:23)特发性,5%(n:20)肢端肥大症,4.8%(n:19)无功能腺瘤,2.3%(n:9)颅咽管瘤。与其他病因导致的高泌乳素血症患者相比,促性腺激素瘤患者的年龄明显偏大,多囊卵巢综合征患者的年龄明显偏小。与其他病因导致的高泌乳素血症相比,催乳素瘤患者的泌乳素水平明显更高,病程也更长(分别为168.00*纳克/毫升(14-23500)[168];8*年(0-39)[5.00]年,*分别为中位值、(最小值-最大值)和[四分位间范围]。除泌乳素瘤外,其他病因组的泌乳素水平无明显差异。令人惊讶的是,我们发现多囊卵巢综合征患者的泌乳素水平高于 100 ng/ml,肢端肥大症或药物引起的高泌乳素血症患者的泌乳素水平高于 200 ng/ml:在我们的研究中,与文献不同的是,巨泌乳素血症可单独出现,也可与其他病症同时出现。除巨泌乳素瘤外,无法根据泌乳素水平进行诊断。与文献类似,催乳素瘤是导致高催乳素血症的最常见原因。高泌乳素血症的病因依次为促性腺激素瘤、药物相关、多囊卵巢综合征、特发性和肢端肥大症。在多囊卵巢综合征中检测到的泌乳素范围被列为新信息。研究发现,儿童组和成人组的病因和泌乳素水平相似:结论:各种生理/病理情况都会增加催乳素水平,催乳素水平也会因人而异。因此,仅凭血清泌乳素水平并不能指导临床诊断或进行鉴别诊断。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.60
自引率
0.00%
发文量
146
期刊最新文献
Diet quality in patients with treatment-resistant schizophrenia: time for improving nutritional recommendations. Zebrafish model in the relentless race to tyrosine kinase inhibitors for neuroendocrine neoplasms. Assessing the impact of a dedicated referral and management algorithm in maternal hypothyroidism. Divulging the overlooked condition: diabetic ketoacidosis as an imminent risk with sodium-glucose co-transporter-2 inhibitors treatment in type 2 diabetes mellitus. Obesity prevention across the lifespan: assessing the efficacy of intervention studies and discussing future challenges.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1